Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Glaukos reported a record-breaking financial performance for both the fourth quarter and full year 2025, showcasing significant growth and operational success across its global business initiatives.</li><li>The company's consolidated net sales reached $143.1 million for the fourth quarter, a 36% increase compared to the previous year, and full-year sales hit $507.4 million, marking a 32% increase from 2024.</li><li>Despite these commendable results, the company maintains a cautious outlook, providing sales guidance for 2026 in the range of $600 million to $620 million, suggesting a projected growth exceeding 20%.</li></ul>

Glaukos reported a record-breaking financial performance for both the fourth quarter and full year 2025, showcasing significant growth and operational success across its global business initiatives.The company's consolidated net sales reached $143.1 million for the fourth quarter, a 36% increase compared to the previous year, and full-year sales hit $507.4 million, marking a 32% increase from 2024.Despite these commendable results, the company maintains a cautious outlook, providing sales guidance for 2026 in the range of $600 million to $620 million, suggesting a projected growth exceeding 20%.

Glaukos: Epioxa Is Replacing Photrexa — But How Quickly Can Access and Coverage Normalize?

<ul><li>Glaukos Corporation recently reported its financial results for the third quarter of 2025, showcasing a significant achievement with record consolidated net sales of $133.5 million.</li><li>This marks a 38% increase on a reported basis compared to the same period last year.</li><li>The company has subsequently raised its full-year 2025 net sales guidance to $490 million - $495 million.</li></ul>

Glaukos Corporation recently reported its financial results for the third quarter of 2025, showcasing a significant achievement with record consolidated net sales of $133.5 million.This marks a 38% increase on a reported basis compared to the same period last year.The company has subsequently raised its full-year 2025 net sales guidance to $490 million - $495 million.

Glaukos: The Niche Epioxa Strategy That Forces A Completely Different Go-To-Market Playbook!

<ul><li>Glaukos Corporation recently delivered its financial results for the first quarter of 2025, reporting a record consolidated net sales figure of $106.7 million, marking a 25% increase on a reported basis or 26% on a constant currency basis when compared to the previous year.</li><li>The company also maintained its full-year net sales guidance range of $475 million to $485 million, even as it navigates the uncertainty of global macroeconomic conditions.</li><li>Baptista Research looks to evaluate the different factors that could influence the company's price in the near future and attempts to carry out an independent valuation of the company using a Discounted Cash Flow (DCF) methodology.</li></ul>

Glaukos Corporation recently delivered its financial results for the first quarter of 2025, reporting a record consolidated net sales figure of $106.7 million, marking a 25% increase on a reported basis or 26% on a constant currency basis when compared to the previous year.The company also maintained its full-year net sales guidance range of $475 million to $485 million, even as it navigates the uncertainty of global macroeconomic conditions.Baptista Research looks to evaluate the different factors that could influence the company's price in the near future and attempts to carry out an independent valuation of the company using a Discounted Cash Flow (DCF) methodology.

Glaukos Corporation: An Insight Into The Latest Advancements in Product Adoption

Technical Analyst, Vermilion Research

Joe Jasper

Technical Analyst

Technical and Quantitative Research

Vermilion Research

Vermilion’s objective is to deliver timely, actionable, and unique technical research to professional investors through the application of our various technical indicators.

Our research strategists seek to highlight securities which we believe are at major inflection points, based on our various technical and quantitative indicators, and offer asymmetric risk/return profiles. Our unique research methodology, centered on relative strength, enables our strategists to deliver superior investment recommendations.

Our process begins by organizing the universe of actively traded stocks into discrete sectors, then into industry groups. We then apply our technical and quantitative tools to identify developing price trends. Once attractive trends are identified within a selected sector or group, we screen for individual stocks which we believe offer the best risk/reward profile. We provide a historical perspective that often reveals, through our long-term charts, how price patterns often repeat themselves over time.

Technical Analysis

The S&amp;P 500’s 5-month uptrend remains intact, and as long as it continues we remain bullish. With that said, we are near the top end of the uptrend channel and could fall 2.75%-3.25% before we get to uptrend support. Overall we believe the positives outweigh the concerns as highlighted in this week's report.  Also highlighted are actionable names in Retailing, Health Care, and small-cap Aero Defense.

The S&amp;P 500’s 5-month uptrend remains intact, and as long as it continues we remain bullish. With that said, we are near the top end of the uptrend channel and could fall 2.75%-3.25% before we get to uptrend support. Overall we believe the positives outweigh the concerns as highlighted in this week's report.  Also highlighted are actionable names in Retailing, Health Care, and small-cap Aero Defense.

S&P 500 Bullish but Extended; Downgrading Financials

<ul><li>Glaukos Corporation's financial results for the fourth quarter and full year 2024 reflect strong performance across multiple segments and considerable strategic initiatives, setting up the company for continued development in the upcoming year.</li><li>The company reported record fourth quarter consolidated net sales of $105.5 million, marking a 28% increase compared to the same period in the previous year.</li><li>For the full year, Glaukos achieved net sales of $383.5 million, representing a 22% increase over 2023.</li></ul>

Glaukos Corporation's financial results for the fourth quarter and full year 2024 reflect strong performance across multiple segments and considerable strategic initiatives, setting up the company for continued development in the upcoming year.The company reported record fourth quarter consolidated net sales of $105.5 million, marking a 28% increase compared to the same period in the previous year.For the full year, Glaukos achieved net sales of $383.5 million, representing a 22% increase over 2023.

Glaukos Corporation: Can The iDose Market Expansion Fetch Significant Growth With iDose Platform?

United States

Glaukos Corporation operates as an ophthalmic medical technology company. The Company develops, manufactures, and markets medical devices for the treatment of glaucoma. Glaukos offers micro-scale injectable therapies designed to address the complete range of glaucoma disease states and progression.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Glaukos Corp (GKOS US)

Glaukos: Epioxa Is Replacing Photrexa — But How Quickly Can Access and Coverage Normalize?

Glaukos reported a record-breaking financial performance for both the fourth quarter and full year 2025, showcasing significant growth and...

Baptista Research

Glaukos: The Niche Epioxa Strategy That Forces A Completely Different Go-To-Market Playbook!

Glaukos Corporation recently reported its financial results for the third quarter of 2025, showcasing a significant achievement with record...

Baptista Research

Glaukos Corporation: An Insight Into The Latest Advancements in Product Adoption

Glaukos Corporation recently delivered its financial results for the first quarter of 2025, reporting a record consolidated net sales figure of...

Baptista Research

S&P 500 Bullish but Extended; Downgrading Financials

The S&P 500’s 5-month uptrend remains intact, and as long as it continues we remain bullish. With that said, we are near the top end of the...

Vermilion Research

Glaukos Corporation: Can The iDose Market Expansion Fetch Significant Growth With iDose Platform?

Glaukos Corporation's financial results for the fourth quarter and full year 2024 reflect strong performance across multiple segments and...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)